AMRX Q3 2024 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q3 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$702M+13.3% YoY

Gross Profit

$270M38.4% margin

Operating Income

$89M12.6% margin

Net Income

-$156,000-0.0% margin

EPS (Diluted)

$-0.00

QoQ Revenue Growth

+0.1%

Cash Flow

Operating Cash Flow

$142M

Free Cash Flow

$121M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$3.5B

Total Liabilities

$3.5B

Stockholders' Equity

-$93M

Cash & Equivalents

$74M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$702M	$620M	+13.3%
Gross Profit	$270M	$233M	+15.9%
Operating Income	$89M	$76M	+17.4%
Net Income	-$156,000	$10M	-101.6%

Revenue Segments

Generics Segment

$427M79%

Amneal Specialty Pharma Segment

$116M21%